191 related articles for article (PubMed ID: 26689752)
1. Anti-inflammatory effect of topical administration of tofacitinib on corneal inflammation.
Sakimoto T; Ishimori A
Exp Eye Res; 2016 Apr; 145():110-117. PubMed ID: 26689752
[TBL] [Abstract][Full Text] [Related]
2. Effects of topical Janus kinase inhibition on ocular surface inflammation and immunity.
Stevenson W; Sadrai Z; Hua J; Kodati S; Huang JF; Chauhan SK; Dana R
Cornea; 2014 Feb; 33(2):177-83. PubMed ID: 24342887
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory effect of IL-6 receptor blockade in corneal alkali burn.
Sakimoto T; Sugaya S; Ishimori A; Sawa M
Exp Eye Res; 2012 Apr; 97(1):98-104. PubMed ID: 22551515
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction.
Meephansan J; Thummakriengkrai J; Ponnikorn S; Yingmema W; Deenonpoe R; Suchonwanit P
Arch Dermatol Res; 2017 Nov; 309(9):729-738. PubMed ID: 28884378
[TBL] [Abstract][Full Text] [Related]
5. Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis.
Fukuyama T; Ehling S; Cook E; Bäumer W
J Pharmacol Exp Ther; 2015 Sep; 354(3):394-405. PubMed ID: 26159873
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.
Huang JF; Yafawi R; Zhang M; McDowell M; Rittenhouse KD; Sace F; Liew SH; Cooper SR; Pickering EH
Ophthalmology; 2012 Jul; 119(7):e43-50. PubMed ID: 22607938
[TBL] [Abstract][Full Text] [Related]
7. Topical Administration of 0.3% Tofacitinib Suppresses M1 Macrophage Polarization and Allograft Corneal Rejection by Blocking STAT1 Activation in the Rat Cornea.
Yu J; Li P; Li Z; Li Y; Luo J; Su W; Liang D
Transl Vis Sci Technol; 2022 Mar; 11(3):34. PubMed ID: 35353151
[TBL] [Abstract][Full Text] [Related]
8. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
[TBL] [Abstract][Full Text] [Related]
9. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
Tanaka Y; Yamaoka K
Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
[TBL] [Abstract][Full Text] [Related]
10. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.
Bissonnette R; Papp KA; Poulin Y; Gooderham M; Raman M; Mallbris L; Wang C; Purohit V; Mamolo C; Papacharalambous J; Ports WC
Br J Dermatol; 2016 Nov; 175(5):902-911. PubMed ID: 27423107
[TBL] [Abstract][Full Text] [Related]
11. Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis.
Morelli M; Scarponi C; Mercurio L; Facchiano F; Pallotta S; Madonna S; Girolomoni G; Albanesi C
J Immunol Res; 2018; 2018():7897263. PubMed ID: 30581877
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of corneal inflammation by the topical use of Ras farnesyltransferase inhibitors: selective inhibition of macrophage localization.
Sonoda K; Sakamoto T; Yoshikawa H; Ashizuka S; Ohshima Y; Kishihara K; Nomoto K; Ishibashi T; Inomata H
Invest Ophthalmol Vis Sci; 1998 Nov; 39(12):2245-51. PubMed ID: 9804132
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
Tanaka Y; Maeshima K; Yamaoka K
Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors.
Gao W; McGarry T; Orr C; McCormick J; Veale DJ; Fearon U
Ann Rheum Dis; 2016 Jan; 75(1):311-5. PubMed ID: 26353790
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
[TBL] [Abstract][Full Text] [Related]
16. Netrin-1 simultaneously suppresses corneal inflammation and neovascularization.
Han Y; Shao Y; Lin Z; Qu YL; Wang H; Zhou Y; Chen W; Chen Y; Chen WL; Hu FR; Li W; Liu Z
Invest Ophthalmol Vis Sci; 2012 Mar; 53(3):1285-95. PubMed ID: 22323486
[TBL] [Abstract][Full Text] [Related]
17. Transient downregulation of microRNA-206 protects alkali burn injury in mouse cornea by regulating connexin 43.
Li X; Zhou H; Tang W; Guo Q; Zhang Y
Int J Clin Exp Pathol; 2015; 8(3):2719-27. PubMed ID: 26045777
[TBL] [Abstract][Full Text] [Related]
18. Fasudil hydrochloride, a potent ROCK inhibitor, inhibits corneal neovascularization after alkali burns in mice.
Zeng P; Pi RB; Li P; Chen RX; Lin LM; He H; Zhou SY
Mol Vis; 2015; 21():688-98. PubMed ID: 26120273
[TBL] [Abstract][Full Text] [Related]
19. Potential Application of Biological Products for the Treatment of Ocular Surface Inflammation.
Sakimoto T
Cornea; 2015 Nov; 34 Suppl 11():S153-7. PubMed ID: 26448173
[TBL] [Abstract][Full Text] [Related]
20. Treatment of halo naevus with the topical Janus kinase inhibitor tofacitinib 1.5.
Hu WT; Lin FQ; Xu AE
Clin Exp Dermatol; 2018 Dec; 43(8):935-937. PubMed ID: 29876955
[No Abstract] [Full Text] [Related]
[Next] [New Search]
